Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern

Bevacizumab has been shown to improve progression-free survival and neurologic function, but failed to improve overall survival in newly diagnosed glioblastoma and at first recurrence. Nonetheless, bevacizumab is widely used in patients with recurrent glioma. However, its use in patients with glioma...

Descripción completa

Detalles Bibliográficos
Autores principales: Burger, Michael C., Mildenberger, Iris C., Wagner, Marlies, Mittelbronn, Michel, Steinbach, Joachim P., Bähr, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412312/
https://www.ncbi.nlm.nih.gov/pubmed/28353668
http://dx.doi.org/10.3390/ijms18040726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412312/
https://www.ncbi.nlm.nih.gov/pubmed/28353668
http://dx.doi.org/10.3390/ijms18040726

Ejemplares similares